Bexagliflozin 20 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 20 mg

Reference Brands: Brenzavvy (USA)

Category: Diabetes

Bexagliflozin is an oral antidiabetic medication belonging to the SGLT2 (Sodium–Glucose Cotransporter 2) inhibitor class. It helps lower blood sugar levels by blocking glucose reabsorption in the kidneys, allowing excess sugar to be excreted through urine. Marketed under the brand name Brenzavvy in the USA, it is available as a 20 mg tablet for once-daily oral use. It is prescribed for adults with type 2 diabetes mellitus to improve glycemic control, along with diet and exercise.

Product Description:

Bexagliflozin is an SGLT2 inhibitor. It blocks the sodium-glucose co-transporter 2 in the proximal tubule of the kidney, the protein that reabsorbs most of the glucose filtered from blood. Blocking it makes the kidney excrete glucose in urine, lowering blood glucose by a mechanism entirely independent of insulin — so it works regardless of how much beta cell function remains.

It is used as an adjunct to diet and exercise in type 2 diabetes. Its position is as a lower-cost entrant to a crowded class: unlike empagliflozin, dapagliflozin and canagliflozin, it does not carry approved cardiovascular or kidney outcome indications, so it competes on glycaemic control and price rather than on organ protection. Class effects apply — genital mycotic infections, volume depletion and hypotension, and euglycaemic diabetic ketoacidosis, which is easy to miss because blood glucose can be near normal. It is not recommended at low kidney function because its glucose-lowering effect depends on filtration.

Sourcing notes. Originator product registered in the US; registration elsewhere is limited, so confirm the destination market. Because the class is now substantially genericised for dapagliflozin and others, price comparison against those generics is the commercial reality for any SGLT2 enquiry.